Treatment of lung cancer

肺癌的治疗

• 批准号: 6819929
• 负责人: DERICK LAU
• 金额: $ 11.39万
• 依托单位: UNIVERSITY OF CALIFORNIA AT DAVIS
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-07-15 至 2009-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6819929
• 关键词: antineoplastics; carboplatin; clinical research; clinical trial phase II; combination cancer therapy; combinatorial chemistry; dosage; enzyme linked immunosorbent assay; high throughput technology; human subject; human therapy evaluation; hypoxia inducible factor 1; immunocytochemistry; ligands; light microscopy; neoplasm /cancer radiation therapy; nonsmall cell lung cancer; paclitaxel; patient oriented research; pharmacokinetics; plasminogen activator inhibitors; tirapazamine; vascular endothelial growth factors

DESCRIPTION (provided by applicant): Lung cancer is the leading cause of cancer death in the United States. The candidate has devoted to clinical and translational research of lung cancer with the hope of improving outcomes for this devastating disease. An area of accomplishment is in the treatment with chemoradiotherapy for poor-risk patients with lung cancer. Another area of expertise of the investigator is in capitalizing the radiosensitizing and antiangiogenic properties of taxol for improving chemoradiotherapy of non-small-cell lung cancer (NSCLC). The candidate was the first researcher to report the in vivo antiangiogenic property of taxol. Clinical trials have demonstrated the feasibility and efficacy of twice-weekly taxol and carboplatin with concurrent radiation for stage III NSCLC. In basic and translational research, the candidate has identified peptide ligands specific for surface receptors of lung cancer cells using the technology of combinatorial chemistry and cell-growth-on-bead assay. A pilot study is being supported by a R21 grant to test the feasibility of using these peptides to capture cancer cells from malignant pleural effusion. The candidate is applying for a K-24 award to support his endeavor of achieving the following aims: 1. To conduct a NCI-sponsored phase II trial in the California Cancer Consortium to test the tolerance and efficacy of tirapazamine in combination with the previously established regimen of twice-weekly taxol and carboplatin with concurrent radiation for stage III NSCLC. A correlative study will explore the feasibility of measuring plasma hypoxia-induced proteins, plasminogen activator inhibitor type I (PAl-l) and vascular endothelial growth factor (VEGF), in association with tumor response before and after chemoradiotherapy. 2. To further develop the peptide-bead technology as a high-yield and high-throughput clinical procedure for isolating and enriching lung cancer cells from pleural fluid. This technology may facilitate the diagnosis of lung cancer. 3. To identify novel peptide ligands specific for lung cancer. The long-term goal is to develop these peptide ligands as molecularly targeted therapy for lung cancer. 4. To recruit and train hematology and oncology specialists in clinical research of cancer therapy.

描述（由申请人提供）：肺癌是美国癌症死亡的主要原因。 该候选人致力于肺癌的临床和转化研究，希望改善这种毁灭性疾病的治疗结果。 一个取得成就的领域是对低危肺癌患者进行放化疗。 研究人员的另一个专业领域是利用紫杉醇的放射增敏和抗血管生成特性来改善非小细胞肺癌（NSCLC）的放化疗。 该候选人是第一个报告紫杉醇体内抗血管生成特性的研究人员。 临床试验已证明每周两次紫杉醇和卡铂联合放射治疗 III 期 NSCLC 的可行性和有效性。 在基础和转化研究中，候选人利用组合化学和细胞珠上生长测定技术鉴定了肺癌细胞表面受体特异性的肽配体。 R21 资助正在支持一项试点研究，以测试使用这些肽从恶性胸腔积液中捕获癌细胞的可行性。 该候选人正在申请 K-24 奖项，以支持他实现以下目标的努力： 1. 在加州癌症联盟开展一项由 NCI 资助的 II 期试验，以测试替拉扎明与先前制定的每周两次紫杉醇和卡铂联合放射治疗 III 期 NSCLC 方案的耐受性和疗效。 一项相关研究将探讨测量血浆缺氧诱导蛋白、I型纤溶酶原激活剂抑制剂(PA1-1)和血管内皮生长因子(VEGF)与放化疗前后肿瘤反应相关的可行性。 2. 进一步开发肽珠技术作为从胸水中分离和富集肺癌细胞的高产率和高通量的临床方法。这项技术可能有助于肺癌的诊断。 3. 鉴定肺癌特异性的新型肽配体。长期目标是开发这些肽配体作为肺癌的分子靶向治疗。 4. 招募和培养从事癌症治疗临床研究的血液学和肿瘤学专家。